Skip to main content

Advertisement

SpringerLink
Log in

Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective

To analyze phenotypic classification and other risk factors for interval breast cancer, focusing on true interval and false negative cancers.

Methods

A nested case–control study was performed among 115 cancers detected between two screening mammograms (interval cancers) and 115 screen-detected cancers diagnosed between 1995 and 2008 in a population-based breast cancer screening program in Barcelona (Spain). Bivariate and multivariate analyses were performed to compare patient and tumor molecular characteristics among all interval cancers, true intervals and false negatives, and screen-detected cancers.

Results

A total of 42.5% of interval cancers were true interval tumors and 16.2% were false negatives. High breast density and triple negative phenotype were more frequent in true interval cancers than in screen-detected cancers (57.6 and 34.1%, respectively for breast density, p = 0.023; 28.1 and 7.5%, respectively for triple negative phenotype, p = 0.028), while no statistically significant differences were observed between false negatives and screen-detected cancers. The main adjusted factors associated with true interval cancers compared with screen-detected cancers were high breast density and triple negative phenotype (OR = 3.1, 95% CI, 1.03–9.24 and OR = 8.9, 95% CI, 2.03–38.62, respectively).

Conclusion

A more aggressive molecular phenotype and high breast density were identified in breast tumors that truly arise in the interval between screenings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rakha EA, El Sayed ME, Reis-Filho JS, Ellis IO (2008) Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 52:67–81

    CAS  PubMed  Google Scholar 

  2. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373:1463–1479

    Article  PubMed  Google Scholar 

  3. Tornberg S, Codd M, Rodrigues V, Segnan N, Ponti A (2005) Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centers. J Med Screen 12:43–49

    Article  PubMed  Google Scholar 

  4. Perry N, Broeders M, de Wolf C, Törnberg C, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg

    Google Scholar 

  5. Vitak B, Olsen KE, Manson JC, Arnesson LG, Stal O (1999) Tumour characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers. Eur Radiol 9:460–469

    Article  CAS  PubMed  Google Scholar 

  6. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ (1996) Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78:1220–1228

    Article  CAS  PubMed  Google Scholar 

  7. Cowan WK, Angus B, Gray JC, Lunt LG, al Tamimi SR (2000) A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 53:140–146

    Article  CAS  PubMed  Google Scholar 

  8. Porter PL, El Bastawissi AY, Mandelson MT (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91:2020–2028

    Article  CAS  PubMed  Google Scholar 

  9. Burrell HC, Sibbering DM, Wilson AR (1996) Screening interval breast cancers: mammographic features and prognosis factors. Radiology 199:811–817

    CAS  PubMed  Google Scholar 

  10. Collett K, Stefansson IM, Eide J (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14:1108–1112

    Article  CAS  PubMed  Google Scholar 

  11. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR (1999) Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:2682–2688

    CAS  PubMed  Google Scholar 

  12. Gilliland FD, Joste N, Stauber PM (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743–749

    Article  CAS  PubMed  Google Scholar 

  13. Palka I, Kelemen G, Ormandi K (2008) Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 14:161–167

    Article  PubMed  Google Scholar 

  14. Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M (2003) Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers. Anticancer Res 23:4213–4218

    CAS  PubMed  Google Scholar 

  15. Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799–2805

    Article  CAS  PubMed  Google Scholar 

  16. Bare M, Sentis M, Galceran J (2008) Interval breast cancers in a community screening programme: frequency, radiological classification and prognostic factors. Eur J Cancer Prev 17:414–421

    Article  PubMed  Google Scholar 

  17. Hofvind S, Geller B, Skaane P (2008) Mammographic features and histopathological findings of interval breast cancers. Acta Radiol 49:975–981

    Article  CAS  PubMed  Google Scholar 

  18. Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118:3112–3117

    Article  CAS  PubMed  Google Scholar 

  19. Mandelson MT, Oestreicher N, Porter PL (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92:1081–1087

    Article  CAS  PubMed  Google Scholar 

  20. Ciatto S, Visioli C, Paci E, Zappa M (2004) Breast density as a determinant of interval cancer at mammographic screening. Br J Cancer 90:393–396

    Article  CAS  PubMed  Google Scholar 

  21. Porter GJ, Evans AJ, Cornford EJ (2007) Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 188:676–683

    Article  PubMed  Google Scholar 

  22. Boyd NF, Rommens JM, Vogt K (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808

    Article  PubMed  Google Scholar 

  23. Harvey JA, Bovbjerg VE (2004) Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 230:29–41

    Article  PubMed  Google Scholar 

  24. Li T, Sun L, Miller N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 14:343–349

    Article  PubMed  Google Scholar 

  25. Guo YP, Martin LJ, Hanna W (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10:243–248

    CAS  PubMed  Google Scholar 

  26. Pike MC, Pearce CL, Wu AH (2004) Prevention of cancers of the breast, endometrium and ovary. Oncogene 23:6379–6391

    Article  CAS  PubMed  Google Scholar 

  27. Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K (2003) Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 95:556–558

    Article  PubMed  Google Scholar 

  28. Kopans DB (2008) Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk. Radiology 246:348–353

    Article  PubMed  Google Scholar 

  29. Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA (2006) Accuracy of assigned BI-RADS breast density category definitions. Acad Radiol 13:1143–1149

    Article  PubMed  Google Scholar 

  30. Kavanagh AM, Cawson J, Byrnes GB (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14:1060–1064

    Article  CAS  PubMed  Google Scholar 

  31. Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8:29–34

    Article  CAS  PubMed  Google Scholar 

  32. Porter GJ, Evans AJ, Burrell HC, Lee AH, Ellis IO, Chakrabarti J (2006) Interval breast cancers: prognostic features and survival by subtype and time since screening. J Med Screen 13:115–122

    Article  PubMed  Google Scholar 

  33. Tan DS, Marchio C, Jones RL (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27–44

    Article  CAS  PubMed  Google Scholar 

  34. Dolle JM, Daling JR, White E (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18:1157–1166

    Article  PubMed  Google Scholar 

  35. Haffty BG, Yang Q, Reiss M (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657

    Article  PubMed  Google Scholar 

  36. Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G (2009) Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 18:479–485

    Article  CAS  PubMed  Google Scholar 

  37. Ciatto S, Catarzi S, Lamberini MP (2007) Interval breast cancers in screening: the effect of mammography review method on classification. Breast 16:646–652

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Cristina Hernández, Rubén Román, Paco Belvis, and Jose María Velarde for their assistance in analysis and data management and Teresa Baró for technical assistance in performing the immunohistochemical analysis. We also thank the Tumor Bank of the Department of Pathology of Hospital del Mar and Xarxa de Bancs de Tumors de Catalunya for providing tissue samples.

Financial support

This study was partially supported by CIBER de Epidemiología y Salud Pública (CIBERESP) [AE08_004], PS09/01285, RD06/0020/0109 (ISCiii/FEDER) and 2009SRG321 (Generalitat de Catalunya).

Author information

Authors and Affiliations

  1. Evaluation and Clinical Epidemiology Department, Hospital del Mar-IMIM, Passeig Marítim, 25-29, 08003, Barcelona, Spain

    Laia Domingo, Maria Sala, Francesc Macià & Xavier Castells

  2. CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

    Laia Domingo, Maria Sala, Francesc Macià, Maria Jesús Quintana & Xavier Castells

  3. EHEA Doctoral Program in Public Health, Department of Pediatrics, Obstetrics and Gynecology, Preventive Medicine and Public Health, Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain

    Laia Domingo & Maria Sala

  4. Medical Oncology, Hospital del Mar-IMIM, Passeig Marítim, 25-29, 08003, Barcelona, Spain

    Sònia Servitja & Joan Albanell

  5. Pathology Department, Hospital del Mar-IMIM, Passeig Marítim, 25-29, 08003, Barcelona, Spain

    Josep Maria Corominas

  6. Radiology Department, CRC-Hospital del Mar, Passeig Marítim, 25-29, 08003, Barcelona, Spain

    Francisco Ferrer & Juan Martínez

  7. Epidemiology Department, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret, 171, 08041, Barcelona, Spain

    Maria Jesús Quintana

Authors
  1. Laia Domingo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Sala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sònia Servitja
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Josep Maria Corominas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francisco Ferrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juan Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesc Macià
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Jesús Quintana
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joan Albanell
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xavier Castells
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Sala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Domingo, L., Sala, M., Servitja, S. et al. Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control 21, 1155–1164 (2010). https://doi.org/10.1007/s10552-010-9541-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-010-9541-6

Keywords

Search

Navigation